Canadian CANNAINVESTOR Magazine May / June 2018 | Page 149

Kate S. Wells

CMO

NanoSphere Health Sciences, Inc.

d: 720.528.4437 | c: 303.324.7358

www.nanospherehealth.com

CSE: NSHS

149

PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.

PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.

NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.

NSHSF: The awarding of this patent cements our place as a leader in nanoparticle delivery and is a significant milestone for our company and our company’s future. We have successfully set the path in front of us for the next five to ten years of our business plan. Our landmark patent for the NanoSphere Delivery System™, means we now officially have ownership of the biggest advancement in non-invasive medical delivery in over 25 years.

Our patent was formally granted on March 27, 2018. This master patent claims and protects our core technology for the formation and manufacturing of structural, lipid nanoparticles, which is the NanoSphere Delivery System™. NanoSphere’s groundbreaking NanoSphere Delivery System™ nanoencapsulates a broad range of bioactive compounds in a protective membrane, which encompasses 16 forms of nanoparticles that will be used in order to vastly improve delivery for a wide array of applications. This patent covers all of our current and expanding divisions - from OTC, beginning with NSAIDS and prescription pharmaceuticals, to cannabis, nutraceuticals and cosmeceuticals.

Our process makes active agents safer, more bioavailable and reduces adverse effects by moving them directly to the bloodstream and delivering precise doses to targeted sites. Our applications include transdermal serum, intranasal and intraoral.

CI: Could you explain your licensing model?

NSHSF: We’re offering a JV licensing model where we lease the equipment and give access to the information on how to produce our products as well as license the brand Evolve itself. We go in, we provide all the equipment and we do all the training to get our partners up and running.

From there, as revenues are generated, costs are allocated. This is a good deal because the licensee is not putting up any of the risk capital. We come in with everything besides the extracted cannabinoids and it’s all covered by Evolve and NanoSphere Health Sciences.

CI:What type of companies would license your technology?

NSHSF: Anyone from pharmaceutical companies to manufacturers of cannabis products. Our NanoSphere Delivery System™ is highly scalable, rapid, cost efficient and occupies a small footprint. By out-licensing our proprietary NanoSphere Delivery technology, our licensees are able to meet their particular requirements.